Chongqing Zhifei Biological Products (300122.SZ): Tetanus vaccine for tetanus approved for clinical trials.

Chongqing Zhifei Biological Products (300122.SZ) announced that the company recently learned that the adsorbed tetanus vaccine developed by its wholly-owned subsidiary, Beijing Zhifei Luluzhu Biological Pharmaceutical Co., Ltd. ("Zhifei Luluzhu"), has received a notice of approval for drug clinical trials from the National Medical Products Administration. The approval allows the product to be used for clinical trials in preventing tetanus. It is reported that the adsorbed tetanus vaccine developed by Zhifei Luluzhu uses column chromatography to purify effective antigens, resulting in higher purity and better immunogenicity compared to traditional salt precipitation purification methods. As of now, there are 12 adsorbed tetanus vaccines available on the market in China according to the National Medical Products Administration website.